3652 results for «231»
3652 results
Insight from new evidence for complex PCI: value of imaging (CHIP IVUS) and left ventricular support (CHIP BCIS 3)
21 May 2026 – From EuroPCR 2026
This session reviews the impact of recent evidence on complex PCI, highlighting the value of intracoronary imaging (CHIP IVUS trial) and left ventricular assist devices (CHIP BCIS 3 trial). Through case discussions, participants reflect on how these innovations influence daily clinical practice and enhance procedural planning...
Left main interventions: pushing the boundaries
21 May 2026 – From EuroPCR 2026
Examine contemporary strategies for distal left main bifurcation disease treatment, including debates on complex bifurcation and high-risk PCI approaches. The session emphasizes the critical role of coronary imaging in guiding decision-making and showcases clinical cases illustrating management of left main interventions under challenging conditions.
Technical decision-making for CTO PCI strategy
22 May 2026 – From EuroPCR 2026
This session focuses on technical decision-making for chronic total occlusion PCI strategy. It presents diverse approaches to right coronary CTOs, complex management involving double rendezvous techniques, subintimal strategies, and innovative single-injection methods, demonstrating the evolving frontiers in CTO intervention.
Unusual clinical cases: thinking beyond the routine
22 May 2026 – From EuroPCR 2026
This session presents unusual and challenging clinical cases that extend beyond routine interventional cardiology. From optimised in-stent restenosis treatment to rare anatomical anomalies and complex thrombus management, it offers valuable lessons in creative problem-solving and advanced intervention techniques.
Atypical NSTEMI culprit lesions
22 May 2026 – From EuroPCR 2026
Focusing on atypical NSTEMI culprit lesions, this session examines rare presentations such as calcific emboli, coronary anomalies, and unusual routes to revascularisation. It provides clinical insights into diagnosing and managing uncommon acute coronary syndromes effectively.
Clinical decision making for CTO PCI strategy
22 May 2026 – From EuroPCR 2026
This session explores clinical decision-making in CTO PCI strategy through complex scenarios including multivessel CTO in ischemic cardiomyopathy, high-risk NSTEMI post-vein graft failure, and challenges in elderly patients. It emphasizes strategic planning and individualized approaches to optimize outcomes.
Overcoming challenging anatomy in calcified lesion PCI
22 May 2026 – From EuroPCR 2026
This session focuses on overcoming the challenges posed by complex anatomical variations in calcified lesion PCI. Experts present advanced techniques and hybrid solutions for difficult bifurcation angles, aorto-ostial lesions, and other complex scenarios, emphasizing both innovative and simplified approaches to achieve procedural success.
Spontaneous coronary artery dissection management with intracoronary imaging
22 May 2026 – From EuroPCR 2026
Explore the nuanced management of spontaneous coronary artery dissection (SCAD) with a focus on intracoronary imaging. This session examines diagnostic challenges, the limited role of coronary CT angiography, and strategies for managing occlusive SCAD cases, highlighting the evolving understanding of this complex condition.
PCR Tokyo Valves 2026: Your travel guide featuring upcoming exclusive booking services and special deals.
Percutaneous or surgical management of post-infarction ventricular septal defects: The United Kingdom National Registry
17 Sep 2022
Elad Asher provides his take on the UK National Registry which was presented at the TCT congress 2022 by Joel Peter Giblett on behalf of the UK PIVSD investigators.
Author
OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease
04 Nov 2021
Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.
Author
EuroPCR 2026 – Long-term mortality following revascularisation for left main disease
20 May 2026
Paris, France, 19−22 May 2026. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during EuroPCR 2026 and are set to impact practice worldwide. Among them is a meta-analysis of long-term data from 4 randomised trials investigating...
